<DOC>
	<DOCNO>NCT00934518</DOCNO>
	<brief_summary>The standard treatment head neck cancer relapse previously irradiate patient controversial . Reirradiation success , many patient still die disease . Cetuximab helpful relapse head neck cancer , improve effectiveness radiation head neck cancer patient . But , studied reirradiation . The purpose study see effect , good bad , reirradiation cetuximab .</brief_summary>
	<brief_title>Image Guided Intensity Modulated Reirradiation ( IG-IMRT ) With Cetuximab Locoregionally Confined Recurrent Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients must pathologically confirm recurrence ( reappearance previously clear ) squamous cell cancer upper aerodigestive tract second squamous cell primary . Patients may experience one recurrence long first recurrence occur ≥6 month follow end prior RT . The recurrence second primary must confine head neck clavicle ( locoregional recurrence ) . The majority ( ≥75 % ) tumor volume must area previously irradiate ≥45 Gy . The previous irradiation must exceed maximum 75 Gy . Patients must least 6 month prior radiation therapy . If resection perform diagnosis recurrence enrollment , either microscopic macroscopic disease must present ( i.e . positive margin gross residual ) . Karnofsky Performance Status 60100 . Granulocytes ≥ 1500/mm3 , platelet ≥ 100,000/mm3 , bilirubin ≤ 1.5 mg/dl , creatinine ≤ 1.5 mg/dl , within 6 week prior registration . Must able submit previous radiation record ( simulation portal film available ) order assure cord tolerance exceed . Patients must sign studyspecific inform consent form prior study entry . The patient must age 18 75 . Distant metastasis . Completely resected recurrence negative margin . Other concurrent invasive malignancy . Prior invasive malignancy unless disease free least two year ( prior situ malignancy permissible ) . Intercurrent medical illness would impair patient tolerance therapy limit survival . Pregnant nursing woman exclude potential teratogenic effect potential unknown effect nurse newborn . Previous treatment cetuximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Squamous cell carcinoma , Head Neck cancer</keyword>
</DOC>